To save money on drugs while encouraging high-value pharmaceutical innovation, we need to better reward value, increase NIH funding for early-stage research, and reduce expenses and risks for developers of drugs whose social value exceeds their financial value.
Funding and Disclosures
Disclosure forms provided by the authors are available at NEJM.org.
This article was published on November 13, 2021, at NEJM.org.
Print Subscriber? Activate your online access.